Terms: = Thyroid cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK
664 results:
1. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
2. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
3. Diffuse coexpression of thyroid transcription factor-1 and p40 in a non-small cell carcinoma of the lung: Second case in the female population.
Segado Martínez M; Ruiz García G
Rev Esp Patol; 2024; 57(2):120-122. PubMed ID: 38599731
[TBL] [Abstract] [Full Text] [Related]
4. TIM3 activates the erk1/2 pathway to promote invasion and migration of thyroid tumors.
Jin X; Yin Z; Li X; Guo H; Wang B; Zhang S; Li Y
PLoS One; 2024; 19(4):e0297695. PubMed ID: 38568917
[TBL] [Abstract] [Full Text] [Related]
5. Carcinoma showing thymus-like elements (CASTLE) with amyloid deposition in the parotid gland.
Hamada M; Miyama Y; Matsumura S; Shintani-Domoto Y; Urano M; Yasuda M
Pathol Int; 2024 Apr; 74(4):227-233. PubMed ID: 38488752
[TBL] [Abstract] [Full Text] [Related]
6. Non-small cell lung carcinoma with focal coexpression of thyroid transcription factor-1 and Δ Np63/p40: A case report.
Terada K; Menju T; Date H; Haga H; Yoshizawa A
Thorac Cancer; 2024 Apr; 15(12):1029-1033. PubMed ID: 38478955
[TBL] [Abstract] [Full Text] [Related]
7. Circ-LDLRAD3/miR-655-3p/mapk1 axis enhances cell migration and invasion in papillary thyroid carcinoma.
Zhang B; Peng Y; Zhou L
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):150-155. PubMed ID: 38430029
[TBL] [Abstract] [Full Text] [Related]
8. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating erk signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract] [Full Text] [Related]
9. thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review.
He J; Xu J; Zheng M; Pan K; Yang L; Ma L; Wang C; Yu J
Chem Biol Interact; 2024 Mar; 391():110909. PubMed ID: 38340975
[TBL] [Abstract] [Full Text] [Related]
10. Discrepancies Between Morphological and Immunohistochemical Classifications Are Associated With Prognoses and Subtypes of Lung cancer.
Natsume K; Ye J; Mukai Y; Yamakawa K; Tanimoto M; Ito H; Miyagi Y; Daigo Y; Muto-Ishizuka M; Kadota K; Haba R; Suizu F
Anticancer Res; 2024 Feb; 44(2):711-722. PubMed ID: 38307593
[TBL] [Abstract] [Full Text] [Related]
11. Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/erk pathway.
Li Y; Fan L; Yan A; Ren X; Zhao Y; Hua B
J Transl Med; 2024 Jan; 22(1):112. PubMed ID: 38282047
[TBL] [Abstract] [Full Text] [Related]
12. Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.
Lee M; Morris LG
Oncotarget; 2024 Jan; 15():36-48. PubMed ID: 38275291
[TBL] [Abstract] [Full Text] [Related]
13. DNMT1/DNMT3a-mediated promoter hypermethylation and transcription activation of ICAM5 augments thyroid carcinoma progression.
Li Z; Ying Y; Zeng X; Liu J; Xie Y; Deng Z; Hu Z; Yang J
Funct Integr Genomics; 2024 Jan; 24(1):12. PubMed ID: 38228798
[TBL] [Abstract] [Full Text] [Related]
14. CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.
Chen X; Shen H; Liu H; Tan L; Zhang N
Funct Integr Genomics; 2024 Jan; 24(1):10. PubMed ID: 38221563
[TBL] [Abstract] [Full Text] [Related]
15. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across cancers.
Shan KS; Rehman TU; Ivanov S; Domingo G; Raez LE
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203795
[TBL] [Abstract] [Full Text] [Related]
16. SLC35A2 expression drives breast cancer progression via erk pathway activation.
Yang X; Tao Y; Xu Y; Cai W; Shao Q
FEBS J; 2024 Apr; 291(7):1483-1505. PubMed ID: 38143314
[TBL] [Abstract] [Full Text] [Related]
17. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar ME; Kim HJ; Kim DR
Signal Transduct Target Ther; 2023 Dec; 8(1):455. PubMed ID: 38105263
[TBL] [Abstract] [Full Text] [Related]
18. Divergent Lineage Markers in Anaplastic thyroid Carcinoma.
Mneimneh WS; Asa SL
Am J Surg Pathol; 2024 Feb; 48(2):230-237. PubMed ID: 37972932
[TBL] [Abstract] [Full Text] [Related]
19. Characterization of the genomic alterations in poorly differentiated thyroid cancer.
Lee Y; Moon S; Seok JY; Lee JH; Nam S; Chung YS
Sci Rep; 2023 Nov; 13(1):19154. PubMed ID: 37932340
[TBL] [Abstract] [Full Text] [Related]
20. FLOT1 promotes gastric cancer progression and metastasis through BCAR1/erk signaling.
Wang R; Huang W; Cai K; Xiao S; Zhang W; Hu X; Guo J; Mao L; Yuan W; Xu Y; Chen Z; Chen Z; Lai C
Int J Biol Sci; 2023; 19(16):5104-5119. PubMed ID: 37928269
[TBL] [Abstract] [Full Text] [Related]
[Next]
